GARDENA, Calif., Oct. 17, 2019 /PRNewswire/ -- For many, Halloween is a time of careless joy, but our dogs rarely share the same stress-free enjoyment of the holiday. But this hasn't stopped dogs owners as this year roughly 16 percent of Americans will dress their dogs up in costumes, spending over $400 million — double what was seen i

CAMBRIDGE, Mass., Oct. 17, 2019 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linke

ROCKVILLE, Md., Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of two posters at the European Society of Gene & Cell Therapy (ESGCT) 27

CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin's Vice President of Pre-Clinical Development, provided a presentation on Palatin's oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Sy

JERSEY CITY, N.J., Oct. 17, 2019 /PRNewswire/ -- Lawsuit Settlement News announced today that they will be expanding their focus on IVC lawsuits, effective immediately. Sources close to the litigation say that swift settlements have not been forthcoming thus far, but LSN expects to see positive developments regarding these cases by the end of 2019.IVC filters are

BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Regulated Information - Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of three Phase 3 studies evaluating the efficacy and safety of bimekizumab, an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe chronic plaque psoriasi

NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital Distric

DUBLIN, Oct. 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release third quarter 2019 financial results on Tuesday, November 5, 2019, prior to the open of U.S. financial markets.

SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced today the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia. The data were presented during the ASHG 2019 Annual Meeting in a poster entitled "Low dose, daily or intermi

ST. LOUIS and DEERFIELD, Ill., Oct. 17, 2019 /PRNewswire/ -- Centene Corporation (NYSE: CNC), Walgreens and RxAdvance today announced a strategic partnership to introduce an innovative model for pharmacy management that aims to increase transparency, enhance customer experience and ultimately result in better health outcomes at lower cost